Dear PennyPicksPro:
Because Amarin had successfully taken FDA
to court, they must make sure that they
are very thorough and not sloppy.
We, the investors get to buy this stock
on the cheap since many investors are on the
fence after the Adcom debacle.
Rest reassured that the Baker brothers have maintained
Their stake in Amarin.
Start planning how you want to cash out. Upon
Topline results or upon a buyout which could
go until second quarter 2019 when they may get a premium
Price.
You know Mendelian genetics randomization predicted that
Increasing hdl will not decrease cardiovascular risks. Yet bigpharma
Has wasted millions in CTEP inhibitors to increase hdl , which failed miserably.
This same genetics approach has predicted through calculation and observation that high level
Of triglyceride cause ischemia in coronary arteries. Yet big pharma
Ignored it in part because hdl level stays constant while triglyceride
Level varies day by day.
Elegant genetics randomization study have proved remnant cholesterol, a marker
For triglyceride caused both ischemia and low grade inflammation while ldl caused
Only ischemia without an inflammatory component.
Since all enrollees will be on optimized Statins all their ldl level will below 100. But the inflammatory component of the remnant cholesterol will Still be there. With 4 grams of EPA the main purpose is to reduce that low grade inflammation. We know from the results of the recent 6 years Cantos study that cardiovascular risks was significantly reduced by decreasing inflammation.
Further , with triglyceride level at below 150, Jelis study reduced risks by 19%.
This was in a Japanese populations , where they already consume a lot of fish. They only
took 1.8 grams of EPA. Thereafter Amarin increased the dose of epa to 4 grams and confirmed that there is a dose dependent benefits and therefore selected 4 grams of EPA for the ReduceIT study. Also Cherry study proved that EPA + Statin Reduce cause plaque regression by 50% compared to statins alone.
Taken together the science is proving that statins plus EPA at 4 grams should dramatically reduce risks of ischemia.
Six years and almost seven months have elapsed since the study started in
December 2011. The topline results will cause a paradigm shift in the prevention/ treatment
Of ischemia and other indications through the SE and TE subgroups.
All the best. Good luck. Be strong.
